ライフサイエンスコーパス: nitric oxide synthase

1 ction, presumably by counteracting inducible nitric oxide synthase.

2 ice with a genetic deficiency of endothelial nitric oxide synthase.

3 ic mediators VEGF receptor 2 and endothelial nitric oxide synthase.

4 ) and preventing its formation by inhibiting nitric oxide synthase.

5 eases in shear and activation of endothelial nitric oxide synthase.

6 rons ( approximately 1%) expressing neuronal nitric oxide synthase.

7 rom erythrocytic xanthine oxidoreductase and nitric-oxide synthase.

8 terin (BH4) is an essential cofactor for all nitric oxide synthases.

9 The role of nitric oxide synthase 1 (NOS1) as a major modulator of c

10 beta-, and gamma-splice variants of neuronal nitric oxide synthase 1 (NOS1), and NOS1beta expression

11 codes for the main NO-producing enzyme, the nitric oxide synthase 1 (NOS1), have been found to conve

12 factor for the production of nitric oxide by nitric oxide synthase 1 (NOS1), major modulator of cardi

13 we have chosen to study the long isoform of nitric oxide synthase 1 adaptor protein (NOS1AP), a prot

14 e with macula densa-specific knockout of all nitric oxide synthase 1 isoforms (MD-NOS1KO) had a signi

15 tulates the previously reported phenotype of nitric oxide synthase 1-deficient mice, which have achal

16 a premature stop codon in the gene encoding nitric oxide synthase 1.

17 taglomerular apparatus of wild-type (WT) and nitric oxide synthase 1alpha-knockout (NOS1alphaKO) mice

18 in 6 (IL6), tumor necrosis factor (TNF), and nitric oxide synthase 2 (NOS2) were studied further.

19 ssue inhibitor of metalloproteinase 1, Dpp4, nitric oxide synthase 2 (Nos2), interleukin 1beta (Il1b)

20 Furthermore, we identified the activity of nitric oxide synthase 2 (NOS2, also known as iNOS) origi

21 luding IL-6, VEGFA, TNFalpha, NFkappaB2, and nitric oxide synthase 2 (NOS2A).

22 of IL-1beta, TNF-alpha, IL-12, and inducible nitric oxide synthase 2 and downregulation of genes asso

23 that therapy requires induced expression of nitric oxide synthase 2 in monocyte-derived dendritic ce

24 decreased the expression of NADPH oxidase 2, nitric oxide synthase 2, and nuclear factor-kappaB1 mRNA

25 Only anti-MDA5 DM showed numerous nitric oxide synthase 2-positive muscle fibers with sarc

26 )) and triple-negative breast cancer (TNBC), nitric oxide synthase-2 (NOS2) and cyclooxygenase-2 (COX

27 ediators including cytokines, chemokines and nitric oxide synthase-2.

28 h is located at 11p14, potentially affecting nitric oxide synthase 3 (NOS3) expression, as shown by m

29 2 genes that mediate nitric oxide signaling (Nitric Oxide Synthase 3 [NOS3] and Guanylate Cyclase 1,

30 Conversely, expression of inducible nitric oxide synthase, a marker of classical activation

31 d indomethacin and inhibition of endothelial nitric oxide synthase abolished the effects of therapeut

32 nd isoform-specific endothelial and neuronal nitric oxide synthase activation and nitric oxide produc

33 ribe a new mechanism for reduced endothelial nitric oxide synthase activation during renal IR that ca

34 m channel activation, attenuated endothelial nitric oxide synthase activation, increased oxidative st

35 eptor and consequently decreased endothelial nitric oxide synthase activation.

36 ory polarization, restoration of endothelial nitric oxide synthase activation.

37 homeostasis, along with reduced endothelial nitric oxide synthase activity, endothelial dysfunction,

38 ons of nuclear factor kappaB and endothelial nitric oxide synthase/Akt/inducible nitric oxide synthas

39 in capillary/arteriole density, endothelial nitric oxide synthase/Akt/vascular endothelial growth fa

40 obese type 2 diabetic mice by an endothelial nitric oxide synthase/Akt/vascular endothelial growth fa

41 tream targets, including Akt and endothelial nitric oxide synthase, although incremental activation b

42 Pathway analysis identified association with nitric oxide synthase and adenosine monophosphate-activa

43 lated from liver expressed reduced inducible nitric oxide synthase and arginase 1 and displayed a red

44 l-MDSC contact and was mediated by inducible nitric oxide synthase and cationic amino acid transporte

45 ated closely with their immunoreactivity for nitric oxide synthase and choline acetyltransferase.

46 EDH), ACh trials were repeated with combined nitric oxide synthase and cyclooxygenase inhibition.

47 ts downstream effectors CD36 and endothelial nitric oxide synthase and cyclooxygenase-2 activity.

48 pregulation of interleukin-1 beta, inducible nitric oxide synthase and cyclooxygenase-2 in the cortex

49 gen species, nitric oxide release, inducible nitric oxide synthase and cycloxygenase-2 expression.

50 nucleotide phosphate-oxidase 2 and inducible nitric oxide synthase and enhanced lung concentrations o

51 Additionally, endothelial nitric oxide synthase and extracellular signal-regulated

52 SIRT1-regulated Akt, endothelial nitric oxide synthase and GLUT4 levels were also induced

53 ased glutathione levels, increased inducible nitric oxide synthase and heme-oxygenase 1 expression, a

54 ased glutathione levels, increased inducible nitric oxide synthase and heme-oxygenase 1 expression, a

55 is attributable to preservation of neuronal nitric oxide synthase and sarcoplasmic reticulum Ca(2+)

56 otein kinase (AMPK) and requires endothelial nitric oxide synthase and soluble guanylyl cyclase.

57 n) of Protein kinase B (Akt) and endothelial nitric oxide synthase and the phosphorylation (inhibitio

58 n) of Protein kinase B (Akt) and endothelial nitric oxide synthase and the phosphorylation (inhibitio

59 1; 2) suppressed the expression of inducible nitric oxide synthase and type I IFN and 3) induced auto

60 e availability of BH4 leads to uncoupling of nitric oxide synthases and production of highly oxidativ

61 lammatory markers (TNFalpha, IL-6, inducible nitric oxide synthase) and a gene for glucose absorption

62 -induced signaling, because Akt, endothelial nitric oxide synthase, and extracellular regulated kinas

63 , involving c-Jun-N-terminal kinases (JNKs), nitric oxide synthase, and intracellular cGMP, exerts a

64 al cell levels of phosphorylated endothelial nitric oxide synthase, and of nitrates and nitrites in c

65 acrophages that expressed IL10 and inducible nitric oxide synthase, and reduced serum levels of inter

66 ltransferase, tyrosine hydroxylase, neuronal nitric oxide synthase, and vasoactive intestinal polypep

67 glial fibrillary acidic protein and neuronal nitric-oxide synthase, and Abeta and p-Tau(Ser-202) also

68 matory proteins (e.g. cyclophilin, inducible nitric oxide synthase, annexins, galectin, cathepsins an

69 Inhibition of endothelial nitric oxide synthase attenuated flow augmentation produ

70 ther IL-17/arginase I or IFN-gamma/inducible nitric oxide synthase axis as suppressor mechanisms.

71 e factor-1alpha, heme oxygenase-1, inducible nitric oxide synthase, B-cell lymphoma-extra large, and

72 by the sigma1-receptor antagonist or various nitric oxide synthase blockers.

73 Inhibition of bacterial nitric oxide synthase (bNOS) has the potential to improv

74 ar endothelial growth factor and endothelial nitric oxide synthase, but the expression of endothelial

75 Arginase 1 (Arg1) and nitric oxide synthases compete for l-arginine to produce

76 mitogen-activated protein kinase (MAPK), and nitric oxide synthase deactivation.

77 (AAV) expressing cKL to diabetic endothelial nitric oxide synthase-deficient mice or alphaKL-null mic

78 wild-type (WT), NO/redox imbalance (neuronal nitric oxide synthase-deficient mice-1 [NOS1(-/-)]), and

79 of ONOO(-)formed from Nox2-derived O2 ()and nitric oxide synthase-derived nitric oxide.

80 Neuregulin production, endothelial nitric oxide synthase dimerization, and Bcl-2 expression

81 opterin concentrations, ratio of endothelial nitric oxide synthase dimers/monomers, and nitric oxide

82 Inhibition of nitric oxide synthase diminished the CORM-3-mediated inc

83 n, shedding of procoagulant MPs, endothelial nitric oxide synthase downregulation, and reduced nitric

84 gh arginase activity, leading to endothelial nitric oxide synthase dysfunction.

85 d it was associated with blunted endothelial nitric oxide synthase (eNOS) activation in skeletal musc

86 s were used, and intervened with endothelial nitric oxide synthase (eNOS) antagonist L-NNA and its ag

87 Endothelial nitric oxide synthase (eNOS) expression was studied in h

88 VEGF-A(164) strikingly increased endothelial nitric oxide synthase (eNOS) expression.

89 ation is impaired due to loss of endothelial nitric oxide synthase (eNOS) function.

90 ear stress-induced activation of endothelial nitric oxide synthase (eNOS) in an endothelial cell.

91 hich was completely abolished by endothelial nitric oxide synthase (eNOS) inhibitor N(G)-nitro-L-argi

92 t-translational modifications of endothelial nitric oxide synthase (eNOS) lead to impaired nitric oxi

93 ty and hypertension by impairing endothelial nitric oxide synthase (eNOS) phosphorylation and promoti

94 re suppressed insulin-stimulated endothelial nitric oxide synthase (eNOS) phosphorylation in skeletal

95 tact with blood to interact with endothelial nitric oxide synthase (eNOS) present in blood.

96 ndeed, RNAi of p47phox inhibited endothelial nitric oxide synthase (eNOS) serine 1179 phosphorylation

97 dysfunction, which is caused by endothelial nitric oxide synthase (eNOS) uncoupling, is an initial s

98 s to AMPK-mediated activation of endothelial nitric oxide synthase (eNOS), enhanced levels of reactiv

99 Instead, expression of endothelial nitric oxide synthase (eNOS), which generates the potent

100 tase (PP2A) dephosphorylation of endothelial nitric oxide synthase (eNOS).

101 t increased tissue expression of endothelial nitric oxide synthase (eNOS).

102 the calmodulin binding domain of endothelial nitric oxide synthase (eNOS, 494-513) and a peptide span

103 Endothelial nitric-oxide synthase (eNOS) and its bioactive product,

104 he stability and activity of the endothelial nitric-oxide synthase (eNOS) and that Cavin-2 knockdown

105 idative stress generally and for endothelial nitric-oxide synthase (eNOS) specifically.

106 mbrane Ca(2+)-ATPase (PMCA), and endothelial nitric-oxide synthase (eNOS).

107 Mechanisms that regulate the nitric oxide synthase enzymes (NOS) are of interest in b

108 phosphorylation, and a decrease in inducible nitric oxide synthase expression both at the cardiac and

109 rotyrosine formation and increased inducible nitric oxide synthase expression.

110 mulation of inflammatory cells and inducible nitric oxide synthase expression.

111 ass II (MHCII) and proinflammatory inducible nitric oxide synthase expression.

112 39 prevented the induction of both inducible nitric-oxide synthase expression and nitric oxide releas

113 crosis factor alpha (TNFalpha) and inducible nitric-oxide synthase expression, indicative of enhanced

114 atter hampered the detachment of endothelial nitric oxide synthase from caveolin-1, leading to an imp

115 ignaling and enhanced myocardial endothelial nitric oxide synthase function and nitric oxide signalin

116 Organophosphate pesticide exposures, nitric oxide synthase gene variants, and gene-pesticide

117 genetic (5-mC, DNMTs), vascular (endothelial nitric oxide synthase), glial (connexin-43, glial fibril

118 PGL-1 induces nitric oxide synthase in infected macrophages, and the r

119 emodelling by over-expression of endothelial nitric oxide synthase in the fat pad of the adult rat me

120 ry cytokines and the mRNA encoding inducible nitric-oxide synthase in both LRP1-expressing and -defic

121 ls, transiently transfected with endothelial nitric oxide synthase, in patients with PAH refractory t

122 de production and muscle phospho-endothelial nitric oxide synthase increased in a stepwise fashion by

123 of pro-inflammatory cytokines and inducible nitric-oxide synthase induction in BV2 cells in a concen

124 in young adults with VVS can be corrected by nitric oxide synthase inhibition, demonstrated with our

125 ing loss of ROV and was eliminated following nitric oxide synthase inhibition.

126 The neuronal nitric oxide synthase inhibitor AAAN (N-(4S)-4-amino-5-[

127 We identify the endogenous endothelial nitric oxide synthase inhibitor ADMA as a biomarker and

128 ced expression of cytokines, and competitive nitric oxide synthase inhibitor Arg1.

129 not corrected by the addition of a neuronal nitric oxide synthase inhibitor indicating that the incr

130 Importantly, infusion of the nitric oxide synthase inhibitor l-N(G)-monomethyl-l-argi

131 tric tissues and these were inhibited by the nitric oxide synthase inhibitor L-NNA.

132 ist phenylephrine (PE), with and without the nitric oxide synthase inhibitor N(G)-monomethyl-L-argini

133 However, in preparations pretreated with the nitric oxide synthase inhibitor N-nitro-l-arginine (l-NN

134 l death in vitro, which was prevented by the nitric oxide synthase inhibitor NG-nitro-l-arginine meth

135 as FoxO4 inactivation and administration of nitric oxide synthase inhibitor to FoxO4 KO mice reverse

136 In 8 healthy subjects, a nitric oxide synthase inhibitor was infused to evaluate

137 AME (N(omega)-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor) abolished flow-mediated

138 etric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are associated with mit

139 a, including those regulating the endogenous nitric oxide synthase inhibitors asymmetrical dimethylar

140 6 (1.5 +/- 0.2-fold; p = 0.02) and inducible nitric oxide synthase (iNOS) (2.4 +/- 0.4-fold; p = 0.01

141 flammatory input through increased inducible nitric oxide synthase (iNOS) activity causes S-nitrosyla

142 Inducible nitric oxide synthase (iNOS) activity increases in acute

143 ne metabolizing enzymes, including inducible nitric oxide synthase (iNOS) and arginase (ARG), are typ

144 Production of inducible nitric oxide synthase (iNOS) and arginase, as well as ot

145 Inducible nitric oxide synthase (iNOS) and B-cell lymphoma-2-assoc

146 adical scavenger and inhibitors of inducible nitric oxide synthase (iNOS) and cathepsin B also revers

147 OPE also had higher NO, inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX-2)

148 ionally, the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2

149 1 target genes, such as TNF-alpha, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2

150 to exhibit prolonged expression of inducible nitric oxide synthase (iNOS) and enhanced killing of per

151 ay that requires the expression of inducible nitric oxide synthase (iNOS) and generation of high leve

152 complex 1 (mTORC1), HIF1alpha and inducible nitric oxide synthase (iNOS) coordinates DC metabolism a

153 Obesity results in perilymphatic inducible nitric oxide synthase (iNOS) expression and accumulation

154 used mainly by enhanced microglial inducible nitric oxide synthase (iNOS) expression and NO release,

155 We show that EFV promotes inducible nitric oxide synthase (iNOS) expression in cultured glia

156 of the NF-kappaB subunit p65; and inducible nitric oxide synthase (iNOS) expression.

157 by genetic deletion of inducible isoform of nitric oxide synthase (iNOS) from VCP TG mouse and by ph

158 Inducible nitric oxide synthase (iNOS) generates nitric oxide (NO)

159 ported that Sal-1 targets cellular inducible nitric oxide synthase (iNOS) in a miRNA manner, leading

160 lyze the role of NADPH oxidase and inducible nitric oxide synthase (iNOS) in a murine model of A. act

161 Increased inflammation and inducible nitric oxide synthase (iNOS) levels characterized the M1

162 ce nitric oxide (NO) or upregulate inducible nitric oxide synthase (iNOS) mRNA following Toll-like re

163 ntributions of TNF, IFN-gamma, and inducible nitric oxide synthase (iNOS) to vaccine efficacy.

164 -gamma), and TNF-alpha, as well as inducible nitric oxide synthase (iNOS) were significantly upregula

165 interferon (IFN)gamma induction of inducible nitric oxide synthase (iNOS), a gene linked to bile duct

166 Both subsets produced Arginase-1, inducible nitric oxide synthase (iNOS), and transforming growth fa

167 ith rapid induction of nitrite and inducible nitric oxide synthase (iNOS), followed by induction of T

168 aB p65-responsive genes, including inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and

169 t a nitric oxide-producing enzyme, inducible nitric oxide synthase (iNOS), is overexpressed under the

170 d HIF-2alpha, leading to decreased inducible-nitric oxide synthase (iNOS), NO-production, and VEGF.

171 endothelial growth factor (VEGF), inducible nitric oxide synthase (iNOS), nuclear factor-kappa B (NF

172 acerbate local tissue damage in an inducible nitric oxide synthase (iNOS)-dependent manner.

173 ule involved in innate immunity is inducible nitric oxide synthase (iNOS).

174 paB that allows hyper-induction of inducible nitric oxide synthase (iNOS).

175 1 (CB1R) and inhibitory effect on inducible nitric oxide synthase (iNOS).

176 proximately 60% of which expressed inducible nitric oxide synthase (iNOS).

177 teins cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS).

178 s and markedly decreased levels of inducible nitric oxide synthase (iNOS).

179 MDSCs inhibited T cells by inducible nitric oxide synthase (iNOS)/nitric oxide (NO), but uniq

180 ms of these factors to control the inducible nitric oxide synthase (iNOS, NOS2).

181 872, P < 0.0005) and expression of inducible nitric oxide synthase (iNOS; r = 0.9986, P < 0.0001).

182 , complement factor D, lactotransferrin, and nitric oxide synthase interacting protein) by quantitati

183 lysaccharide-induced expression of inducible nitric oxide synthase, interleukin-1beta, and interleuki

184 s factor alpha, interleukin-1beta, inducible nitric oxide synthase, interleukin-6, and gamma interfer

185 Finally, treatment of diabetic endothelial nitric oxide synthase knockout mice with selexipag augme

186 Furthermore, macrophages from inducible nitric oxide synthase knockout mice, which had intact RO

187 st, affects development of DN in endothelial nitric oxide synthase-knockout db/db mice.

188 Mice lacking a functional endothelial nitric oxide synthase (KO, NOS3(-/-) ) and wild-type mic

189 SC were treated with inhibitors of inducible nitric oxide synthase (L-NAME and NCX-4016).

190 dichlorofluorescein diacetate dye, inducible nitric oxide synthase levels determined by Western blot,

191 6) and decreased the expression of inducible nitric oxide synthase (M1 marker).

192 neuronal (neuron-specific enolase, neuronal nitric oxide synthase) markers in IR(Akita) compared wit

193 ated signalling through Akt, the endothelial nitric oxide synthase mediated pathway, regulates anabol

194 Among these is neuronal nitric oxide synthase mu (nNOSmu), which requires specif

195 triggers calmodulin-dependent activation of nitric oxide synthase, nitric oxide (NO) production, NO-

196 ce through a tetrahydrobiopterin/endothelial nitric oxide synthase/nitric oxide pathway.

197 el of human enteric neuropathy, the neuronal nitric oxide synthase (nNOS(-/-)) deficient mouse model,

198 itors while retaining the potency for neural nitric oxide synthase (nNOS) and selectivity over the ot

199 agonist mecamylamine, inhibitors of neuronal nitric oxide synthase (nNOS) and soluble guanylyl cyclas

200 al interneurons, immunoreactive for neuronal nitric oxide synthase (nNOS) and the receptor NK1, expre

201 he nitric oxide synthesizing enzyme neuronal nitric oxide synthase (nNOS) in nerve fibers of the muri

202 Neuronal nitric oxide synthase (nNOS) inhibition is a promising s

203 pic glutamate receptor5 (mGluR5) on neuronal nitric oxide synthase (nNOS) interneurons.

204 Inhibition of neuronal nitric oxide synthase (nNOS) is a promising therapeutic

205 Neuronal nitric oxide synthase (nNOS) is a target for development

206 Selective inhibition of neuronal nitric oxide synthase (nNOS) is an important therapeutic

207 xcess nitric oxide (NO) produced by neuronal nitric oxide synthase (nNOS) is implicated in neurodegen

208 se in the dimer to monomer ratio of neuronal nitric oxide synthase (nNOS) protein and lowered NOS act

209 tion that depended on activation of neuronal nitric oxide synthase (nNOS).

210 pendent reduction in dystrophin and neuronal nitric oxide synthase (nNOS, also known as NOS1) on atri

211 Citrulline formation by both human neuronal nitric-oxide synthase (nNOS) and mouse macrophage induci

212 scle is the muscle-specific form of neuronal nitric oxide synthase (nNOSmu) produced by the NOS1 gene

213 tuberculosis esxL induced the expression of nitric-oxide synthase, NO production, and p38 MAPK pathw

214 as associated with uncoupling of endothelial nitric oxide synthase (NOS) activity secondary to oxidat

215 pre-established heart disease independent of nitric oxide synthase (NOS) activity, whereas PDE5A inhi

216 utaneous vasodilatation and sweating through nitric oxide synthase (NOS) and calcium-activated potass

217 diated by prostacyclin-induced activation of nitric oxide synthase (NOS) and calcium-activated potass

218 nt expression of NMDA receptors (NMDARs) and nitric oxide synthase (NOS) and is therefore much more s

219 Nitric oxide synthase (NOS) catalyzes the conversion of

220 oduction from the amino acid l-arginine, via nitric oxide synthase (NOS) enzymes, research in recent

221 Nitric oxide synthase (NOS) genes are candidates for Par

222 ytotoxic effects, which are inhibited by the nitric oxide synthase (NOS) inhibitor L-NIO, and genetic

223 se (nNOS) and selectivity over the other two nitric oxide synthase (NOS) isoforms (endothelial NOS an

224 ase, during hyperoxia, defective endothelial nitric oxide synthase (NOS) produces reactive oxygen and

225 e dystrophin-sarcoglycan complex delocalizes nitric oxide synthase (NOS) to alter its signaling, and

226 Oxidative stress and nitric oxide synthase (NOS) uncoupling are thought to co

227 This imbalance leads to nitric oxide synthase (NOS) uncoupling with reduced nitr

228 -monomethyl-L -arginine (L -NMMA) to inhibit nitric oxide synthase (NOS), the posture-induced increas

229 aneous vasodilatation and sweating through a nitric oxide synthase (NOS)-dependent mechanism.

230 aneous vasodilatation and sweating through a nitric oxide synthase (NOS)-dependent mechanism.

231 ersion of l-arginine into citrulline through nitric oxide synthase (NOS).

232 Nitric oxide synthases (NOS) are important mediators of

233 Donor administration of the nitric oxide synthases (NOS) co-factor tetrahydrobiopter

234 rophin protein completely abolishes muscular nitric-oxide synthase (NOS) function as a regulator of b

235 lytic cascade triggered by activating type 2 nitric-oxide synthase (NOS-2) and NADPH oxidase (NOX).

236 s by mitochondria, NADPH oxidase, and type 2 nitric-oxide synthase (NOS-2) and resulted in S-nitrosyl

237 ion increased in the presence of l-arginine (nitric-oxide synthase [NOS] substrate), and it decreased

238 is of the nitrergic neurons (with the enzyme nitric oxide synthase; NOS) has helped in understanding

239 ary to mRNA encoding the neuronal isoform of nitric oxide synthase (Nos1) is expressed in the mouse b

240 hat protein kinase Cbeta (PKCbeta) and brain nitric oxide synthase (NOS1), both identified by proteom

241 the metalloproteinase ADAMTS1 and inducible nitric oxide synthase (NOS2) as therapeutic targets in i

242 racellular adhesion molecule 1 (ICAM-1), and nitric oxide synthase (NOS2), developed leukostasis and

243 -regulated genes in BV-2 microglia including nitric oxide synthase (NOS2), interleukin-6 (IL-6), and

244 ells are phenotypically similar to inducible nitric oxide synthase (NOS2)- and tumor necrosis factor

245 thyl transferase (COMT(-/-)) and endothelial nitric oxide synthase (Nos3(-/-)) knockout mice, would b

246 y intact cells, is controlled by endothelial nitric oxide synthase (NOS3) and is crucial for attenuat

247 ation to pregnancy, as knockout mice lacking nitric oxide synthase (NOS3) have abnormal utero-placent

248 in, apelin receptor (APLNR), and endothelial nitric oxide synthase (NOS3) in HA adaptation and HA pul

249 etes was induced in hypertensive endothelial nitric oxide synthase (Nos3)-deficient mice by five low-

250 ochromes P450, the buildup of I435 occurs in nitric oxide synthases (NOSs) upon their reaction with e

251 ng aromatic amino acid hydroxylases (AAAHs), nitric oxide synthases (NOSs), and alkylglycerol monooxy

252 e improves insulin resistance in endothelial nitric oxide synthase null mice, and multiple studies ha

253 del, STZ-induced diabetes in the endothelial nitric oxide synthase-null (eNOS(-/-)) mice.

254 eam signaling pathways involving endothelial nitric oxide synthase or prostanoid production (indometh

255 crosis factor-alpha (P = 0.04) and inducible nitric oxide synthase (P = 0.02) in skin biopsy specimen

256 anifested by decreased levels of endothelial nitric oxide synthase (P< .005) and Kruppel-like factor

257 In contrast, inhibition of nitric-oxide synthase, p38 MAPK, and G9a abrogated H3K9m

258 othelial nitric oxide synthase/Akt/inducible nitric oxide synthase pathways were assessed by Western

259 by siRNA significantly increased endothelial nitric oxide synthase phosphorylation at threonine 495 l

260 c oxide production and decreased endothelial nitric oxide synthase phosphorylation at threonine 495 l

261 cardiac GLUT4 translocation and endothelial nitric oxide synthase phosphorylation were blunted 7 day

262 tivation, an increase in Akt and endothelial nitric oxide synthase phosphorylation, and a decrease in

263 nels (K(Ca)3.1 and K(Ca)2.3) and endothelial nitric oxide synthase, produces additive tone, which is

264 s an activated endothelium and for inducible nitric oxide synthase production upon HGF stimulation.

265 ty to use N via the ornithine-urea cycle and nitric oxide synthase production.

266 of capon (C-terminal PDZ ligand of neuronal nitric-oxide synthase protein), apoptosis-associated spe

267 opterin, dimeric and phosphorylated neuronal nitric oxide synthase, sarcoplasmic reticulum Ca(2+) han

268 dimerization and phosphorylation of neuronal nitric oxide synthase, sarcoplasmic reticulum Ca(2+) rel

269 actility, tetrahydrobiopterin, the dimers of nitric oxide synthase, sarcoplasmic reticulum Ca(2+) rel

270 activation by fluvoxamine triggered the Akt-nitric oxide synthase signaling pathway, resulting in ti

271 capillaries via the NMDA receptors-neuronal nitric oxide synthase signaling pathway.

272 sociated variant-BPIFB4 restores endothelial nitric oxide synthase signaling, rescues endothelial dys

273 ivity for vasoactive intestinal polypeptide, nitric oxide synthase, somatostatin, and vesicular gluta

274 trulline (L-Cit) is converted to endothelial nitric oxide synthase substrate, L-arginine.

275 uM(vgat/vglut2)) and another also expressing nitric oxide synthase (SuM(Nos1/Vglut2)).

276 volves the activation of the Akt-endothelial nitric oxide synthase survival pathway, and the inhibiti

277 volves the activation of the Akt-endothelial nitric oxide synthase survival pathway, and the inhibiti

278 6, multiple PDZ protein 1, Tamalin, neuronal nitric oxide synthase, syntrophins, protein interacting

279 ry cytokine tumor necrosis factor, inducible nitric oxide synthase, the M1 activator interferon gamma

280 effects alter the expression of endothelial nitric oxide synthase, the stability of atherosclerotic

281 Intriguingly, eNOS activity is regulated by nitric-oxide synthase trafficking inducer (NOSTRIN), whi

282 Seven to 50 million endothelial nitric oxide synthase-transfected endothelial progenitor

283 ssion of proinflammatory proteins (inducible nitric oxide synthase, tumor necrosis factor-alpha, and

284 ssion of proinflammatory proteins (inducible nitric oxide synthase, tumor necrosis factor-alpha, and

285 t radiation disrupted BH4, which resulted in nitric oxide synthases uncoupling and augmented radiatio

286 Neuronal nitric-oxide synthase, unlike its endothelial and induci

287 Caffeine down-regulated endothelial nitric oxide synthase, vascular endothelial growth facto

288 relevant changes in the vascular endothelial nitric oxide synthase vasodilatory response, which is a

289 tion that could be restored by inhibition of nitric oxide synthase via the inhibitor N-nitro-l-methyl

290 Notably, plasma arginine use by nitric oxide synthase was decreased in infected mice.

291 allografts, whereas expression of inducible nitric oxide synthase was decreased.

292 progenitor cells overexpressing endothelial nitric oxide synthase was tolerated hemodynamically in p

293 ression of Nos2, the gene encoding inducible nitric oxide synthase, was elevated in the absence of PP

294 e dismutase were increased, whereas those of nitric oxide synthase were decreased, in 7- to 10-week-o

295 , cyclooxygenase 2 and inducible endothelial nitric oxide synthase, were assessed in peripheral blood

296 adhesion molecule-1 (VCAM-1) and endothelial nitric oxide synthase, whereas PDEs had significantly hi

297 activation of a phagosomal enzyme, inducible nitric oxide synthase, which is necessary for NO product

298 he production of nitric oxide by endothelial nitric-oxide synthase, which ascorbate is known to activ

299 c contractions persisted until inhibition of nitric oxide synthase with N(omega) -nitro-l-arginine me

300 howed higher levels of phosphorylated neural nitric oxide synthase within neural stem cells (NSCs).